Italy) (details in Data S1); the 100 kDa allergen recognized by one of these patients was characterized by mass spectrometry (details in Data S1). Statistical methods as well as ethical issues are detailed in the Data S1; probability levels < 5% were considered statistically significant. Further, asthma severity also depended on the number allergen components recognized (no asthma < mild < moderate < severe asthma; [r = 0.166; P = 0.0001]).
The association between number of molecules recognized and asthma was confirmed in patients monosensitized to HDM.
Asthmatics recognized on average 2.26 molecules vs 1.70 in nonasthmatics (P < 0.005), and the number of components recognized by nonasthmatics, patients with mild asthma, or patients with moderate/severe asthma was 1.79 (SD 1.16), 2.06 (1.14), and 2,58 (0.99), respectively (P < 0.05 for moderate/severe vs mild asthma and P < 0.001 for moderate/severe asthmatic vs nonasthmatic patients).
In monosensitized patients, asthma was strongly associated with This study shows that asthma prevails in multisensitized patients suggesting an increased inflammation of lower airways in this subpopulation. Further, it confirms that asthma prevalence and severity depend on the number of HDM molecules recognized. 6, 7 The higher severity of rhinitis and asthma in males needs further investigation. In vitro studies show that measuring both D1 and D2 IgE is needed to diagnose HDM allergy, as 5% are monosensitized. However, D1/D2-negative patients are often Der p 23 reactors confirming that Der p 23 is underrepresented in HDM extracts. 9 Further, HDM allergy diagnosis cannot rely on the current panel of components only as 13% of patients react to currently unavailable high mw allergens, one of them 
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